You just read:

DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting

News provided by

DelMar Pharmaceuticals, Inc.

Nov 21, 2017, 15:06 ET